The pharmaceutical company AstraZeneca has announced that experimental medicine sonnesitoug vdoti has received priority screening status from the American Food and Barnat Administration ( The FDA, to treat some patients with advanced stomach cancer.
The results of the clinical study of the third stage showed that the drug reduced the risk of dying for patients by 42 percent compared with other treatments used in the study.

According to the results, patients who took the drug had an average survival of 10.6 months, compared to 6.4 months in those who received alternative treatment.
The medicine targets a particular protein in cancer cells in order to attack the tumor more directly.
The FDA’s final decision is expected during the second quarter of 2027.
The signal where the truth speaks before the news!
Source Layer: Signal





